CASE REPORTS
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Analysis of pseudoprogression after corneal cross-linking in children with progressive keratoconus.

Acta Ophthalmologica 2016 November
PURPOSE: To analyse the long-term efficacy of corneal cross-linking (CXL) in children with keratoconus and to describe criteria for the detection of pseudoprogression.

METHODS: Evaluation of retrospectively collected corneal topography (Placido system) and tomography (Scheimpflug system) results after CXL in children (age 18 or younger). Twenty-five patients (33 eyes) were included. Follow-up was assessed after 1, 2, 3 and 4 years. Progression was defined as an increase in maximal keratometry (Kmax) of at least one dioptre (D) in 1 year.

RESULTS: For the entire group, mean Kmax prior to CXL was 55.3 ± 7.3D and decreased significantly (p = 0.00001) after 1 year to 53.4 ± 7.4D. In 23 patients, the progression could be halted. Five cases of presumed progression were identified. One case showed marked steepening in Kmax 4 years after CXL, but the topographic parameters were unchanged. The tomography was repeated and showed that Kmax was stable. Two cases with limbal vernal keratoconjunctivitis (VKC) worsened both in corneal tomography and topography. After resolution of the limbal inflammation, the Kmax values returned to the values before the inflammation. We found two cases of true progression both of which had advanced keratoconus prior to CXL with a preoperative Kmax of 64.4, respectively, 75.1D.

CONCLUSION: Our results confirm that CXL is effective in stabilizing keratoconus in children. True progression after CXL could only be verified in two of 33 eyes in a follow-up period of 37.5 months (SD ± 10 months). Two different measuring methods can help to detect diagnostic discrepancies and prevent false conclusions. Moreover, limbal vernal changes can cause transient pseudoprogression, reversible upon sufficient treatment.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app